Calbioreagents has released six monoclonal antibodies for MRSA.
MRSA are strains of Staphylococcus aureus that have developed resistance to beta lactam antibiotics.
Resistance to these antibiotics is mediated by the MRSA MecA gene and the resulting mutant penicillin binding protein 2a (PBP2a).
A series of monoclonal antibodies specific for the MRSA PBP2a protein have been developed by Calbioreagents' partner company Dinona in Korea, and are available exclusively through Calbioreagents.
The six PBP2a antibodies are suitable for the development of immunoassays to differentiate MRSA from methicillin-sensitive S aureus.
Calbioreagents MRSA products include matched pairs of antibodies and a PBP2a recombinant protein.
